View More Recent Stories

Oct 31, 2024 04:11PM Kymera Therapeutics (KYMR) PT Raised to $59 at Jefferies
Oct 31, 2024 07:36AM Kymera Therapeutics (KYMR) Tops Q3 EPS by 1c
Oct 9, 2024 07:01AM Kymera Therapeutics (KYMR) Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
Sep 27, 2024 06:32AM Kymera Therapeutics (KYMR) PT Raised to $56 at Oppenheimer
Sep 25, 2024 07:01AM Kymera Therapeutics (KYMR) Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
Sep 9, 2024 12:07PM Leerink Partners Assumes Kymera Therapeutics (KYMR) at Outperform, 'We have a more cautious view on KT-474'
Aug 26, 2024 02:55PM Kymera Therapeutics (KYMR) October 50 puts active on bid
Aug 26, 2024 06:03AM Wolfe Research Upgrades Kymera Therapeutics (KYMR) to Outperform
Aug 20, 2024 06:12AM Kymera Therapeutics (KYMR) Prices $225M Offering at $40.75/sh
Aug 19, 2024 04:01PM Kymera Therapeutics (KYMR) Announces $200M Proposed Public Offering
Aug 8, 2024 06:37AM Kymera Therapeutics (KYMR) PT Raised to $60 at H.C. Wainwright
Aug 7, 2024 07:49AM Kymera Therapeutics (KYMR) Tops Q2 EPS by 10c
Jul 9, 2024 07:35AM Kymera Therapeutics (KYMR) PT Raised to $36 at B.Riley
Jul 9, 2024 07:27AM TD Cowen Reiterates Buy Rating on Kymera Therapeutics (KYMR)
Jul 8, 2024 05:10PM After-hours movers: Intel, Helios, Zapp Electric Vehicles Group and more
Jul 8, 2024 04:05PM Kymera Therapeutics (KYMR) Announces Expansion of KT-474 HS and AD Phase 2 Studies
Jun 17, 2024 08:17AM Piper Sandler Reiterates Overweight Rating on Kymera Therapeutics (KYMR)
Jun 17, 2024 06:42AM H.C. Wainwright Reiterates Buy Rating on Kymera Therapeutics (KYMR)
Jun 14, 2024 07:01AM Kymera Therapeutics (KYMR) Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
View More Recent Stories